A Safety and Efficacy Study of T0903131 (INT131) Besylate to Treat Type 2 Diabetes Mellitus

PHASE2CompletedINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

December 31, 2003

Study Completion Date

June 30, 2004

Conditions
Diabetes Mellitus, Type II
Interventions
DRUG

T0903131 Besylate

Once daily, oral

DRUG

Placebo

Once daily, oral

Trial Locations (21)

Unknown

Whittier Diabetes Institute, La Jolla

Charles R. Drew University, Los Angeles

National Research Institute, Los Angeles

Lovelace Research Institute, Santa Ana

University of Miami, Miami

GFI Research Center, Evansville

Joslin Diabetes Center, Boston

Radiant Research, Edina

Radiant Research, St Louis

St Louis Center for Clinical Research, St Louis

Kaleida Health Diabetes Center, Buffalo

Rochester Clinical Research, Rochester

Duke University Medical Center, Durham

Radiant Research, Portland

Radiant Research, Anderson

Baylor University Endocrine Center, Dallas

Dallas Diabetes and Endocrine Research Center, Dallas

Endocrine Associates of Dallas, Dallas

Diabetes and Grandular Disease Clinic and Reseach Center, San Antonio

Endocrine Research Specialists, Ogden

Salem VA Medical Center, Salem

Sponsors
All Listed Sponsors
lead

InteKrin Therapeutics, Inc.

INDUSTRY